Bill > HB1426

This bill establishes a comprehensive regulatory framework for "liability shield products" in Indiana, which are defined as medical, pharmaceutical, biological, or technological products that have been designated as immune from liability under federal law. The legislation requires manufacturers to conduct a placebo-controlled study lasting at least five years on these products before they can be distributed, manufactured, marketed, or administered within the state. The study must collect and publicly disclose safety outcome metrics, including potential impacts on allergenicity, carcinogenicity, fertility, immunogenicity, mutagenicity, and reactogenicity. The Indiana Department of Health is mandated to monitor adverse outcomes through health information exchanges and vaccine event reporting systems, and must publish post-market surveillance data. Manufacturers must submit documentation proving the initiation of a placebo-controlled study by July 1, 2028, and a compliance report with final results by December 31, 2030. The bill also provides legal protections for individuals, allowing them to refuse these products without coercion and granting them the right to seek injunctive relief, compensatory damages, and attorney's fees if harmed. Additionally, the attorney general can bring actions against entities that violate the chapter's requirements, with potential civil penalties of up to $100,000 per violation.

Health and Social Services

https://iga.in.gov/legislative/2025/bills/house/1426/details